Bardet-Biedl Syndrome: Clinical Trials

18 trials for Bardet-Biedl Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 6 recruiting, 1 active not recruiting, 1 approved for marketing. 3 Phase 3, 2 Not applicable, 1 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3
Not applicable2Completed 1, Recruiting 1
Phase 21Withdrawn 1
Phase 41Recruiting 1

Follow Bardet-Biedl Syndrome: new trials by email Literature Review of Bardet-Biedl Syndrome trials Research Report on Bardet-Biedl Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bardet Beidle Syndrome in a Syrian Adolescent : a Rare Case Report
Bardet Biedl Syndrome (BBS)
UnknownAl Baath University1002024-10-122024-09-27
Early Genetic Identification of Obesity
Genetic testing via blood collection - Obesity, Childhood, Hyperphagia
Active not recruitingRolfs Consulting und Verwaltungs-GmbH (RCV)10002024-01-242025-09-29
Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
Setmelanotide - Bardet Biedl Syndrome (BBS), Bardet Biedl Syndrome
Phase 4RecruitingTom Hühne2002023-01-012026-06-29
The Effect of GLP1 Agonists on Weight Loss in BBS Cohort in the UK
Bardet-Biedl Syndrome
CompletedThe Queen Elizabeth Hospital3002023-01-012026-05-27
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Setmelanotide - Bardet-Biedl Syndrome, POMC Deficiency Obesity
Phase 3CompletedRhythm Pharmaceuticals, Inc.122022-03-082024-11-27
Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome
No intervention - Bardet-Biedl Syndrome
CompletedOslo University Hospital302022-02-012025-08-07
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg - Bardet-Biedl Syndrome, POMC Deficiency
Phase 3CompletedRhythm Pharmaceuticals, Inc.192021-12-212024-11-26
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)
Blood sample, Urine sample - Ciliopathies, Nephronophthisis
Not applicableCompletedAssistance Publique - Hôpitaux de Paris2402021-11-082026-05-06
COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study
Skin biopsy - Bardet-Biedl Syndrome, Alström Syndrome
Not applicableRecruitingUniversity Hospital, Strasbourg, France3502020-06-162021-09-10
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Setmelanotide, Placebo - Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Phase 3CompletedRhythm Pharmaceuticals, Inc.522018-11-232023-12-01
GROWing Up With Rare GENEtic Syndromes
Retrospective file studies - Prader-Willi Syndrome, PWS-like Syndrome
Recruitingdr. Laura C. G. de Graaff-Herder6002018-10-012023-09-06
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
Metformin - Bardet-Biedl Syndrome, Visual Impairment
Phase 2WithdrawnUniversity Hospital Tuebingen2018-04-012019-04-18
Clinical Registry Investigating Bardet-Biedl Syndrome
Bardet-Biedl Syndrome
RecruitingMarshfield Clinic Research Foundation12002014-06-012022-07-19
Inherited Retinal Degenerative Disease Registry
Eye Diseases Hereditary, Retinal Disease
RecruitingFoundation Fighting Blindness200002014-06-012026-05-19
ARPKD Database Study
Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease
RecruitingChildren's Hospital of Philadelphia2002011-06-012026-06-15
Genetics and Clinical Characteristics of Bardet-Biedl Syndrome
Bardet-Biedl Syndrome
TerminatedNational Human Genome Research Institute (NHGRI)1942004-02-172019-12-04
Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults
clinical, biological, and radiological - Bardet-Biedl Syndrome, Orphan Diseases
CompletedUniversity Hospital, Strasbourg, France402003-06-012008-08-08
An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)
Setmelanotide, administered subcutaneously [SC], once daily. - Bardet-Biedl Syndrome (BBS), Obesity
Approved for marketingRhythm Pharmaceuticals, Inc.2022-08-10

Narrower conditions

Obesity (7)  ·  Alstrom Syndrome (3)  ·  Hyperphagia (3)  ·  Polydactyly (3)  ·  Proopiomelanocortin Deficiency (3)  ·  Retinal Diseases (3)  ·  Retinitis Pigmentosa (3)  ·  Agenesis of Cerebellar Vermis (2)  ·  Genetic Diseases, Inborn (2)  ·  Nephronophthisis, familial juvenile (2)  ·  Pediatric Obesity (2)  ·  22q11 Deletion Syndrome (1)  ·  Abetalipoproteinemia (1)  ·  Achromatopsia 3 (1)

Broader conditions

Abnormalities, Multiple (18)  ·  Brain Diseases (18)  ·  Central Nervous System Diseases (18)  ·  Congenital Abnormalities (18)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18)  ·  Eye Diseases (18)  ·  Hypothalamic Diseases (18)  ·  Nervous System Diseases (18)  ·  Ciliopathies (17)  ·  Eye Diseases, Hereditary (17)  ·  Genetic Diseases, Inborn (16)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Retinitis Pigmentosa (15)  ·  Signs and Symptoms (14)  ·  Nutritional and Metabolic Diseases (11)

Interventions

setmelanotide (5)  ·  Biological Products (1)  ·  Blood Specimen Collection (1)  ·  Metformin (1)

Sponsors

Rhythm Pharmaceuticals, Inc. (4)  ·  University Hospital, Strasbourg, France (2)  ·  Al Baath University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Children's Hospital of Philadelphia (1)  ·  Foundation Fighting Blindness (1)  ·  Marshfield Clinic Research Foundation (1)  ·  National Human Genome Research Institute (NHGRI) (1)  ·  Oslo University Hospital (1)  ·  Rolfs Consulting und Verwaltungs-GmbH (RCV) (1)  ·  The Queen Elizabeth Hospital (1)  ·  Tom Hühne (1)  ·  University Hospital Tuebingen (1)  ·  dr. Laura C. G. de Graaff-Herder (1)

Countries

United States (7)  ·  France (4)  ·  United Kingdom (4)  ·  Germany (3)  ·  Canada (2)  ·  Netherlands (2)  ·  Puerto Rico (2)  ·  Spain (2)  ·  Australia (1)  ·  Norway (1)

Top investigators

David Meeker, MD (3)  ·  Alain Verloes, MD (1)  ·  Arndt Rolfs, PhD, MD (1)  ·  Catherine Arnold, MD (1)  ·  Charlotte von der Lippe, MD, PhD (1)  ·  Christian Brandt, MD (1)  ·  Didier Lacombe, MD (1)  ·  Heiko Billing, PD Dr. med. (1)  ·  J-Louis Mandel, MD (1)  ·  Jeremy Tomlinson, Professor (1)  ·  Leslie G Biesecker, M.D. (1)  ·  Linda Shapiro, M.D., Ph.D. (1)  ·  Lisa Guay-Woodford, MD (1)  ·  Metin Cetiner, PD Dr. med. (1)

Results publications

PMID 34013094, PMID 36356613, PMID 36647077, PMID 36961653, PMID 39549719, PMID 40262952, PMID 40903014, PMID 41703984, PMID 42157030, PMID 42175648, PMID 42821228

NIH funding

2018 (1), P30DK074038 (1)